Ibogaine : A Novel Anti-Addictive Compound. A Comprehensive Literature Review Jonathan Freedlander Journal of Drug Education and Awareness, 2003 https://www.researchgate.net/publication/287670047_Ibogaine_A_novel_anti-addictive_compound Introduction and History Ibogaine is a naturally occurring indole alkaloid, found in a variety of African shrubs of the Tabernathe genus (Obach, Pablo, and Mash, 1998). The root of the Tabernanthe iboga plant (also known as eboga) is the most frequently cited source of ibogaine, and this plant contains 11 other known psychoactive constituents (Popik, and Skolnick, 1999). Chemically, ibogaine is classified as a tryptamine, being a rigid analogue of melatonin, and is structurally similar to harmaline, another natural alkaloid and psychedelic (Xu et al, [...]
Lire la suitePharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies Ismael Apud The Journal of Transpersonal Psychology, 2016, Vol. 48, No. 2, 150-167. ABSTRACT: In the second half of the twentieth century, when psychopharmacology was not developed as we know it today and psychoanalysis was an influential school, various psychiatrists began to develop a ‘pharmacology of consciousness,’ and became interested in hallucinogens as new paths for accessing the unconscious. However, with the psychedelic model, the pharmacology of consciousness turned also into a ‘pharmacology of spirituality,’ focused on the use of spiritual experiences as catalyzers of psychological change. This article [...]
Lire la suitePowerful substances in tiny amounts: Exploring the practice of microdosing psychedelic drugs Petter Grahl Johnstad Working Paper · December 2017 Nordic Studies on Alcohol and Drugs, 2018, Vol. 35(1) 39–51. Doi : 10.1177/1455072517753339 This article presents an explorative study of microdosing practices with psychedelic drugs. A microdose is defined as a sub-perceptual dose, commonly about one tenth of an ordinary recreational dose, which gives no alteration of consciousness or feeling of intoxication. Respondents (n = 17) were recruited at several Internet fora for individual interviews mediated via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job [...]
Lire la suiteLong-term follow-up of psilocybin-facilitated smoking cessation Johnson M.W., Garcia-Romeu A., Griffiths R.R. The American Journal of Drug and Alcohol Abuse, 2017, 43, (1), 55–60 http://dx.doi.org/10.3109/00952990.2016.1170135 Abstract Background : A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives : To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods : The present [...]
Lire la suiteLong-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]
Lire la suiteN, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen : Past, Present, and Future Research to Determine Its Role and Function Steven A. Barker Frontiers in Neuroscience, 2018, 12, 536. doi: 10.3389/fnins.2018.00536 This report provides a historical overview of research concerning the endogenous hallucinogen N, N-dimethyltryptamine (DMT), focusing on data regarding its biosynthesis and metabolism in the brain and peripheral tissues, methods and results for DMT detection in body fluids and brain, new sites of action for DMT, and new data regarding its possible physiological and therapeutic roles. Research that further elaborates its consideration as a putative neurotransmitter is also addressed. Taking these studies together, the report [...]
Lire la suiteBIBLIOGRAPHIE : Ayahuasca Neurophysiologie, Pharmacologie, Thérapeutique et Chamanisme Dr Christian Sueur, GRECC, janvier 2020 22 pages 1 - Ayahuasca : généralités : 1 - 5 2 - Neurophysiologie de l’ayahuasca : 6 -8 3 - Pharmacologie de l’ayahuasca : 9 4 - Ayahuasca et Thérapeutique : 12 - 17 5 - Ayahuasca, spiritualité et Chamanisme :18 - 23
Lire la suite